Compare ARK Space & Defense Innovation ETF (ARKX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Neurocrine Biosciences Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.43, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $185.50 |
52-Week Low | $25.46 | $123.10 |
Market Cap | — | $16.76B |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.27, up 3.82% today, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 suggests overbought conditions. The ETF focuses on space exploration and innovation, holding positions in companies like SpaceX and Rocket Lab, benefiting from strong sector tailwinds and recent SpaceX IPO momentum.
Outlook is positive due to growth in the space economy, but risks include high volatility and stretched valuations in key holdings. Investors should weigh exposure to speculative tech against potential regulatory and competitive pressures in the evolving market.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
